Baird Medical Investment Holdings Ltd (BDMD) Stock Analysis
Verdict: AVOID
Acute liquidity squeeze and severe net losses overwhelm MWA commercial distribution news, leaving cash runway under two months.
Investment score: 24/100
Analysis as of
Is Baird Medical Investment Holdings Ltd stock worth reviewing? The TradeMates thesis
The TradeMates model views BDMD as an extreme distress case. While commercial distribution deals demonstrate ongoing product validity, cash runway is functionally exhausted.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Baird Medical Investment Holdings Ltd opportunities and risks
What speaks for BDMD
- Strategic Distribution Expansion with China Resources Pharma
What speaks against BDMD
- Terminal Cash Exhaustion and Insolvency Risk
Peers and competitors
- 3600.HK
- 1612.HK
- 630.HK
Frequently asked questions about Baird Medical Investment Holdings Ltd (BDMD)
Is BDMD stock a good investment?
The TradeMates model rates Baird Medical Investment Holdings Ltd as AVOID with an investment score of 24/100. The TradeMates model views BDMD as an extreme distress case. While commercial distribution deals demonstrate ongoing product validity, cash runway is functionally exhausted. This is algorithmic model output, not personal investment advice.
Is BDMD stock a buy?
The TradeMates model verdict for BDMD is AVOID with an investment score of 24/100. Treat this as a model signal to review, not a personal buy recommendation.